Incyte Corporation INCY
123.36
(1.46)
(1.17%)
as of 29 Sep
- Market cap
- $26.1B
- P/E
- 15.4×
Follow INCY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Incyte Corporation (INCY) Net margin
Incyte Corporation's net margin over the twelve months to 30 June 2026 was 27.7%, up 2.7 percentage points from fiscal 2025 (25.0%). Over the past ten years it has ranged from −20.4% (fiscal 2017) to 31.8% (fiscal 2021); the current reading is higher than 91% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 25.0% | 24.26 |
| FY2024 | 0.77% | (15.40) |
| FY2023 | 16.2% | 6.13 |
| FY2022 | 10.0% | (21.72) |
| FY2021 | 31.8% | 42.85 |
| FY2020 | −11.1% | (31.79) |
| FY2019 | 20.7% | 14.88 |
| FY2018 | 5.82% | 26.20 |
| FY2017 | −20.4% | (29.81) |
| FY2016 | 9.43% | 8.56 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 35.0% | 11.15 |
| Mar 2026 | 23.8% | 3.97 |
| Dec 2025 | 19.9% | (11.19) |
| Sep 2025 | 31.1% | (2.27) |
| 42 more quarters | Free account |
Against its own ten years
Low −20.4%
High 31.8%
Ten-year median
9.43%
Current reading's percentile
91
Net margin against peers
| Company | Net margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 32.0% |
| INCY Incyte Corporation | 27.7% |
| JAZZ Jazz Pharmaceuticals PLC compare | 20.5% |
| GMAB Genmab A/S Sponsored ADR compare | 19.1% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 16.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.7% |
| BNTX BioNTech SE Sponsored ADR compare | −65.8% |
| INSM Insmed, Inc. compare | −76.9% |
| ROIV Roivant Sciences Ltd. compare | −3,535.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.53% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement